Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Industry Can’t Endure Further Price Cuts for Creating Savings: LDP Health Affairs Chief
November 14, 2023
- Generic Study Group Discusses Industry Shake-Up through Consortia
November 14, 2023
- Japan Health Minister Seeks Industry Input for Detailed Discussions on Innovation Ecosystem
November 14, 2023
- Pfizer’s PARP Inhibitor, RSV Vaccine, Lilly’s IL-13 Med UP for Panel Review on Nov. 27
November 14, 2023
- 1.4 Billion Yen Booked as Emergency Subsidy for Drug Production Ramp-Up: FY2023 Extra Budget
November 13, 2023
- Japan Looks to Bolster Drug Discovery, Earmarks 240 Million Yen in FY2023 Extra Budget
November 13, 2023
- Generic Study Group Not Bound by Year-End Goal to Compile Final Report, Explore Best Solutions: MHLW Official
November 13, 2023
- Shionogi’s Cefiderocol Selected for Pilot-Based Revenue Assurance System
November 13, 2023
- Revisit 25-Plus-Year Listing Requirement for Essential Drugs: Chuikyo Members
November 13, 2023
- MHLW Proposes New Premium with Easier-than-Sakigake Requirements to Fight Lag, Loss
November 13, 2023
- Japan Panel Supports Certain Out-of-Pocket Payment for LLP-Generic Price Gap
November 10, 2023
- MHLW Proposes NIP Inclusion of 15-Valent Pneumococcal Vaccine for Kids
November 10, 2023
- Industry Prods Careful Debate on Creating Separate Rules for Leqembi Re-Pricing
November 9, 2023
- MHLW Cautions against Hoarding Oseltamivir Dry Syrup amid Tight Stocks
November 9, 2023
- Chugai’s Fujihara, Alfresa’s Arakawa to Represent Industry at Chuikyo
November 9, 2023
- Accumulate Knowledge to Prevent Dementia, a “National Issue”: PM Advisor
November 8, 2023
- Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
- Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
November 8, 2023
- LDP Lawmakers Air Concerns over MOF Push for Negative Fee Revision
November 8, 2023
- Abecma Clears Japan Panel Review for 3rd Line MM Use
November 7, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…